Inrebic

Inrebic is a medicine used to treat adults with myelofibrosis (a rare form of blood cancer) who have enlarged spleen or other symptoms related to the disease. Inrebic can be used in three types of the disease: primary myelofibrosis (also known as chronic idiopathic myelofibrosis, where the cause is unknown), post\-polycythaemia vera myelofibrosis (where the disease is linked to an overproduction of red blood cells) and post\-essential thrombocythaemia myelofibrosis (where the disease is linked to an overproduction of platelets, components that help the blood to clot). Inrebic is used both in patients who have not been treated with medicines known as Janus kinase (JAK) inhibitors before and in those who have been treated with the JAK inhibitor ruxolitinib. These diseases are rare, and Inrebic was designated an ‘orphan medicine’ (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicines Agency’s website ([primary myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-794): 1 October 2010; [post\-polycythaemia vera myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-811): 26 November 2010; [post\-essential thrombocythaemia myelofibrosis](/en/medicines/human/orphan-designations/eu-3-10-810): 26 November 2010\). Inrebic contains the active substance fedratinib.